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Abstract
Purpose Developmental dysplasia of the hip (DDH) is
common, and the term encompasses a spectrum of ana-
tomical abnormalities of the hip in which the femoral head
displaces from the acetabulum. These abnormalities may
be congenital or develop during infancy and/or childhood.
Neither the prenatal and postnatal factors that predispose to
hip instability nor the determinants of its resolution or
persistence are well characterised. A multifactorial patho-
genesis of DDH is commonly accepted and identified risk
factors include a family history, being first born, breech
presentation, female gender, high birth weight and oligo-
hydramnios 1. Further to genetic factors, a number of
nutritional, hormonal and mechanical influences on liga-
ment laxity have been hypothesised.
Methods A comprehensive search was conducted using
NICE Healthcare Databases Advanced Search and Google
Scholar engines, and the terms ‘‘nutrition’’, ‘‘environmen-
tal’’, ‘‘risk factors’’, ‘‘CDH’’ and ‘‘DDH’’. Wherever pos-
sible, evidence from randomised controlled trials,
systematic reviews and expert review articles published in
the medical and veterinary literature was considered.
Results The relationship between a number of hormones
and biochemical markers of nutritional status and the
development of DDH has been repeatedly hypothesised
upon in the last 45 years. Of those most frequently cited are
calcium, vitamins C and D, and relaxin hormone. The
evidence for these potential risk factors is provided mainly
by canine studies, with a paucity of consistent or strong
evidence in humans.
Conclusions DDH is common and remains a leading cause
of hip osteoarthritis in young adults. Neonatal clinical
screening programmes for this condition have been in practice
since the 1950s, albeit with varying levels of sensitivity. This
review summarises current understanding of some of the most
frequently cited nongenetic hypothesised risk factors, the
significance of which remain to be determined.
Keywords Developmental dysplasia of the hip (DDH) 
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Clinical relevance
Improved characterisation of a number of possible envi-
ronmental risk factors would advance accurate identifica-
tion of not only those at risk of DDH, but also differentiation
between infants with hip instability that is like to resolve
and those in which it may persist. The establishment of a
large clinical inception cohort study would provide a valu-
able data set, from which hypothesis generation for further
focussed studies may subsequently be developed.
Environmental factors implicated in human
developmental dysplasia of the hip
Developmental dysplasia of the hip (DDH) is common and
remains a leading cause of hip osteoarthritis in young
adults. Predating Ortolani’s well-recognised work in the
1900s, the first published report of clinical hip instability is
believed to have been in 1879 [1]. That DDH continues to
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be regarded as ‘‘mysterious, protean and unresolved’’ [2]
pertains to its intriguing complexity.
The term DDH encompasses a spectrum of anatomical
abnormalities of the hip, which may be either congenital or
develop during infancy and/or childhood. A multifactorial
pathogenesis of DDH is commonly accepted. A broad
range of risk factors is quoted in textbooks and journals.
These include being first born, female gender, high birth
weight, oligohydramnios, talipes (calcaneo valgus or equ-
ino varus), a family history and breech presentation. Of
these, only the latter two are recommended in national
screening programme guidelines to identify at-risk babies
for secondary screening [3].
Neonatal clinical screening programmes for DDH have
been in practice since the 1950s, accompanied by considerable
debate as to their effectiveness and impact on functional
outcome. The importance of early diagnosis, however, is
universally acknowledged: the earlier the detection, the sim-
pler and more effective the treatment. An increasing burden on
secondary ultrasound screening services at a rate of 5 % year
on year [4] propels the need for improved characterisation of
risk factors predisposing to DDH. Furthermore, the signifi-
cance of these risk factors in differentiating cases of resolution
versus those that persist remains unknown.
How can detection of DDH be improved?
Review of the current understanding of the aetiology and
pathophysiology of DDH reveals evidence for both genetic
[5] and environmental contributions to DDH. Hypothesised
environmental risk factors may be broadly categorised as
epidemiological, nutritional, hormonal and connective tis-
sue composition (Table 1).
Epidemiological
There is recognised variation in the incidence rate of DDH
worldwide—ranging from 0.1 to [10 % [6]. Highest inci-
dence populations can be found in Finland, Croatia and
Canada (5–195 per 1,000), with very low incidences
amongst populations in sub-Saharan Africa and Hong Kong
(0–0.1 per 1,000) [7]. Geographical and cultural factors
regarding climate differences and the practice of swaddling
respectively may in part explain this variation [8, 9].
Within individual populations, DDH prevalence can
show marked seasonal variation [10–12]. Although the
trend has been most commonly observed with an inclination
towards the winter months, the converse is reported in
Finland with a peak in the months of June and July [13].
Current evidence lacks consistency, and as Siffel et al. [14]
recommended, more robust analytical approaches such as
time-series analyses are required [14]. Progress is under-
way: the first study to mathematically model the birth month
of children with DDH was published earlier this year,
demonstrating seasonal variation across all groups (both
hemispheres), with peak incidences most frequently
observed in mid-March and mid-October [15]. As
acknowledged by the study’s authors, to make sense of these
patterns of seasonal variation, we must understand their role
Table 1 Summary of




1. Epidemological Age Gestation
Parity Birth order
Ethnicity Gender
Month of conception Date, season of birth
2. Nutritional Weight, height (BMI) Birthweight
Use of dietary supplements Growth (height, weight)
Alcohol history Breast/bottle milk
Smoking history Age of weaning
Serum Vitamin C Vitamin C
Vitamin D Vitamin D
Calcium Calcium
3. Hormonal Hormonal contraception use
Serum Relaxin Relaxin
Breast milk Relaxin Prolidase
Urine Oestrogens Oestrogens
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in the context of a wider complex interplay of extrinsic
physical, intrinsic physical, metabolic and genetic factors.
Nutritional
Nutrition plays a major role in the development of canine
DDH. In genetically predisposed dogs, a number of dietary
excesses are believed to increase the frequency and severity
of hip dysplasia. Excess energy consumption or ‘overnu-
trition’ is associated with rapid growth rates and relative
overloading of the skeleton. This is believed to increase the
frequency and severity of DDH in genetically susceptible
dogs, most markedly if in the first 6 months of life [16].
The two main aetiological categories in canine hip
dysplasia (CDH) have been proposed as abnormal pro-
gression of endochondral ossification and hip joint laxity
causing instability [17]. Relating these principles to diet,
young dogs lack a protective mechanism against excess
dietary calcium [16]. High levels of calcium delay endo-
chondral ossification and skeletal remodelling by reducing
osteoclastic activity. Excess vitamin D, by increasing
intestinal absorption and renal resorption of calcium, is
believed to be similarly harmful in dogs genetically pre-
disposed to DDH.
Regarding the interaction between diet and hip joint
laxity, the importance of vitamin C for healthy collagen
synthesis is well understood and was previously believed to
be protective against canine DDH [18]. The administration
of high dose dietary vitamin C in the controlled clinical
setting has however failed to support this theory [19]. In
addition, some studies show that excess vitamin C causes
hypercalcaemia and delayed bone remodelling as described
above [20].
Unlike young dogs, neonates exhibit protective para-
thyroid, renal and skeletal regulatory mechanisms to con-
trol calcium and vitamin D levels. To the best of our
knowledge, no data have been published regarding mater-
nal and neonatal levels of calcium, or vitamins D or C, and
risk of DDH.
Hormonal
Relaxin is a 6-kDa polypeptide pregnancy hormone that
increases the secretion of collagenase and plasminogen
activator—two important enzymes for collagenolysis. Two
main hypotheses for the role of relaxin in DDH exist. The
first describes its direct effect on foetal ligament laxity by
influencing connective tissue metabolism alongside oes-
trogens and progesterone. Higher and more prolonged
levels of relaxin have been reported in canine serum of
animals with hip dysplasia [21] and in the cord blood
serum of babies with hip dysplasia compared to those
without hip pathology (28.7 vs. 19.8 pg/ml [22]). This
however did not reach statistical significance (p = 0.086)
in a cohort size of 24 babies, and subsequent investigation
has failed to show an association between umbilical vein
blood relaxin levels and neonatal hip instability [23].
A contradicting hypothesis exists to explain a higher
incidence of DDH with lower relaxin concentrations. One
of the main assumed functions of relaxin is relaxation of
the mother’s pelvic ligaments to prepare the birth canal for
parturition. A study has shown lower relaxin concentra-
tions in the cord blood of newborns with clinical symptoms
of hip instability compared to newborns with inconspicu-
ous hip findings. Hence, an association between lower
relaxin levels and poorer preparation of the pelvis has been
suggested to cause higher pressures to be exerted on the
foetus perinatally [24]. This indirect influence of relaxin
fits with a longstanding theory that intrauterine pressure or
that developed during delivery may contribute to hip
instability [25, 26].
The direct effects of oestrogen and progesterone on the
collagen and elastin content of the joint capsule have been
investigated in animal models. These show an increased
rate of hip dislocation with administration of progesterone
versus a protective effect with administration of oestrogen
[27].
Urine analysis has thus far shown no significant differ-
ences in oestrogen output between newborns with DDH
and matched controls [28]. However a positive correlation
between serum progresterone and serum relaxin concen-
tration has been reported, with attenuation of serum relaxin
concentration associated with use of hormonal contracep-
tion [29].
The ubiquity of relaxin and a lack of clear definition for
its many actions make for an obvious focus of further
studies. A greater understanding of relaxin receptor
expression of the developing foetal hip and hence the
possibility of varying susceptibilities to this hormone is
required.
Connective tissue composition
Connective tissue disorders include a spectrum of cartilage,
collagen, fibrillin and matrix protein abnormalities. In
1978, Ponseti described his theory of acetabular cartilage
dysplasia following histological analysis of six infants with
DDH [30]. The pathological changes documented include a
loss of proteoglycans and an increase in collagen deposi-
tion in the lateral acetabular roof, manifesting as a ridge of
degenerating acetabular cartilage—detected clinically as a
positive Ortolani sign.
Systemically, recognition of associated joint hypermo-
bility and of inguinal hernias in children with DDH has
directed the focus of a number of studies to identify dif-
ferences in collagen content, distribution and metabolism
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of the joint capsule and ligaments [31–34]. The specific
appearance of hernias abnormally early in life favours the
hypothesised role of relaxin exerting its effects on colla-
genase in these infants.
Prolidase is a cytosolic exopeptidase that plays a crucial
role in collagen degradation and in the recycling of proline.
Increased serum prolidase activity in patients with DDH
suggests increased collagen turnover, with a positive cor-
relation reported between prolidase level and disease
severity [35]. Soran et al. [35] compared 36 DDH patients
to 33 controls, all between the ages of 9 and 18 months.
Larger population studies, to also include a wider age
range, are required to show consistency and add power to
these findings. It is as yet unclear whether and how proli-
dase activity may be a useful marker in differentiating
between cases of DDH likely to resolve or persist.
Risk stratification: baby steps to refined screening
Our review of the most up-to-date evidence highlights the
need for better characterisation of the natural history of
human DDH. Efforts to improve detection of DDH have
been based on identification of infants at increased risk.
Neither the prenatal and postnatal factors that predispose to
hip instability nor the determinants of its resolution or
persistence are well understood.
A number of epidemiological, nutritional, hormonal and
connective tissue influences on ligament laxity have been
hypothesised. Evidence for these potential risk factors is
however provided largely by canine studies, with a paucity
of consistent or strong evidence in humans. Specifically,
we lack large prospective studies that capture the breadth
of the environmental risk factors hypothesised. Such
studies would provide data to aid the design of further
focussed, high-quality human studies of specific, poten-
tially modifiable maternal, pre- and antenatal risk factors
for DDH. In turn, we may progress towards a clearer
understanding of the origins of early degenerative hip
disease, using robust evidence to best direct screening and
surgical resources in the future.
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